samedan logo
 
 
 
spacer
home > ebr > autumn 2016 > in the genes
PUBLICATIONS
European Biopharmaceutical Review

In the Genes

Many people take pleasure in knowing that the phrase “D’oh” originates from the TV series ‘The Simpsons’, whereas those who really know smugly attribute it to Jimmy Finlayson from the Laurel and Hardy films of the 1920s and 1930s. In much the same way, many people think that stem cells and gene-editing are also new inventions. Indeed, if one were to anthropomorphise two of the newest biotechnology tools, most people would regard stem cell technology as a junior-school prodigy, and its younger brother, gene-editing, as a precocious preschooler.

This year, 2016, does indeed mark the tenth anniversary of the first description of pluripotent stem cells induced from mammalian adult fibroblast cultures by defined factors – and fewer than four years ago, a programmable, dual-RNA-guided DNA endonuclease called Cas9 caught the imagination of thousands of laboratories across the globe. Variants of these tools have enjoyed a long and successful history, winning Nobel prizes and saving lives long before their current incarnations were even a glint in their inventors’ eyes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Patrick Harrison is a Molecular Biologist at University College Cork, and his research is sponsored by the Cystic Fibrosis Trust. He began using gene-editing as a research tool for rare diseases in 2005, and his group was the first to publish a gene-editing strategy to correct the most common CF mutation in cells using ZFNs. His lab is currently using CRISPR-Cas9 and Cpf1 to study CF and other rare diseases, including cystinosis and epidermolysis bullosa.
spacer
Patrick Harrison
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Brain Mapping Pioneer Omniscient Neurotechnology Raises AUD 40 Million in Series B Financing

Omniscient Neurotechnology (“o8t™”), a pioneering brain mapping technology company, today announced the completion of an AUD 40 million Series B financing round. The funding was led by family offices and high-net worth individuals, including Hancock Prospecting’s Executive Chairman Mrs. Gina Rinehart, and prominent fund manager Will Vicars.
More info >>

White Papers

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

Temptime Corporation

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
More info >>

 
Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement